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Statement of clinical relevance: 
 
OPMDs may progress to oral cancer, but assessment of the risk for an individual patient is 
difficult. This review describes the most important risk factors and presents an approach to 
risk assessment at each stage of the clinical evaluation of a patient. 
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Abstract 
Oral potentially malignant disorders (OPMD) have a stastically increased risk of progessing 
to cancer, but the risk varies according to a range of patient or lesion related factors. It is 
difficult to predict the risk of progression for any individual patient and the clinician must 
make a judgement based an assessment of each case.  The most commonly encountered 
OPMD is leukoplakia, but others including lichen planus, oral submucous fibrosis and 
erythroplakia may also be seen.  Factors associated with an increased risk of malignant 
transformation include gender, the site and type of lesion, habits such as smoking and 
alcohol and the presence of epithelial dysplasia on histologic examination. In this review we 
attempt to identify the important risk factors, and present a simple algorithm that can be used 
as a guide for risk assessment at each stage of the clinical evaluation of a patient. 
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Introduction 
 
The terminology of oral lesions, which may have the potential to progress to malignancy has 
varied over the years. At a World Health Organisation (WHO) workshop in 2007, it was 
recommended that the distinction between potentially malignant lesions and conditions 
should be abandoned in favour of a common terminology of oral potentially malignant 
disorders (OPMD) (1,2) and this has now been accepted in the latest WHO classification (3). 
The term OPMD recognises the fact that even in patients with a defined lesion, such as 
leukoplakia, malignancy may arise elsewhere in the oral cavity as a result of field change, 
even in clinically normal mucosa (4,5).  There are a number of disorders which have been 
associated with an increased risk of squamous cell carcinoma, including leukoplakia, 
erythroplakia, oral lichen planus, oral submucous fibrosis, actinic cheilitis, palatal lesions of 
reverse cigar smoking, discoid lupus erythematosus, and some inherited disorders such as 
dyskeratosis congenita and FDQFRQL¶VDQDHPLDFrom a clinical perspective, the vast majority 
of lesions of concern present as white patches, with or without a speckled or red component, 
and many of these will not have a specific diagnosis and must be managed as leukoplakia.  
Although these disorders have an increased statistical risk of malignant change, it is very 
difficult to predict the outcome for an individual patient. This review will focus on leukoplakia 
but other disorders will be mentioned where there is evidence of any defined risk factors. 
 
The prognosis of oral potentially malignant disorders 
The definition of leukoplakia remains unsatisfactory, but essentially it refers to a white lesion 
of the oral mucosa, that cannot be defined as a known disease or disorder and carries an 
increased risk of progressing to cancer (1-6). However, leukoplakia is a dynamic lesion 
which may vary in texture or colour over time, DQGLVQRWDOZD\V³ZKLWH´,QGHHGOHXNRSODNLDV
deemed to be at most risk are often speckled red and white lesions.  Pure red lesions, or 
erythroplakia are much rarer, but have the greatest risk for malignant change (7). Although 
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progression to cancer is the most important outcome, only relatively few lesions progress 
and the remainder may persist unchanged, may enlarge or reduce in size, or may even 
resolve completely.  Features that may be associated with increased risk of progression to 
malignancy are listed in Table 1, with our estimate of the strength of the association. 
Explanatory notes and relevant references are found in the following sections. 
 
Clinical prognostic factors for progression to cancer 
Site 
The location of a lesion within the mouth may influence the risk of malignant transformation, 
but this is almost certainly related to aetiological factors and therefore may vary by 
geographical location and local habits.  For example, in betel quid chewers the buccal 
mucosa is likely to be the most affected site, while in the developed world where smoked 
tobacco and alcohol are the most important aetiological factors, the floor of the mouth and 
lateral border of the tongue, are the most common sites for OPMD and oral cancer.  In a UK 
study of 630 patients with dysplastic lesions, over 95% were leukoplakias and the most 
common sites (42% of lesions) were the lateral and ventral tongue and floor of the mouth 
(8). In addition, lesions at these sites were more likely to show severe epithelial dysplasia. 
Conversely, only 21% of lesions arose on the buccal mucosa, and these were mostly mild 
dysplasia.  In a similar study in Australia, Dost et al (9) found that the buccal mucosa was 
the single most common site for OPMDs (31% of lesions in which 50% of these were OLP), 
but 40% were on the tongue and in the floor of the mouth. However, lesions on the tongue 
and floor of mouth were more likely to be dysplastic or malignant (OR. 2.6: p=0.005). It is 
noteworthy to recognise that ventral of tongue and floor of mouth are contiguous anatomic 
VLWHVDQGVRPHDXWKRUVGRQ¶WVSHFLI\WKHH[act location of a lesion on tongue surfaces. This 
may warrant a careful interpretation of the findings. In a cross-sectional study of 3,256 
leukoplakias in the USA, the highest prevalence of severe dysplasia or carcinoma-in-situ 
was in the floor of mouth (13.5%) and tongue (5%) (10). These data suggest that these sites 
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are at the highest risk, but studies of actual malignant transformation have shown variable 
findings.  
In Hungary, although only 8.2% of leukoplakias arose on the tongue, these accounted for 
37.5% of lesions that underwent malignant transformation, equivalent to a transformation 
rate of 27% for tongue leukoplakias (11).  Floor of mouth also had a high transformation rate 
with 13% of lesions developing into cancer.  In contrast, although most of the leukoplakias 
(63%) were found on the buccal mucosa, only 4.0% of these lesions progressed (11).  
Similar data have been reported in England, where two studies showed high transformation 
rates of 24% (12) and 16% (13) for leukoplakias in the floor of the mouth (sublingual 
keratosis). 
In contrast, some studies have been unable to establish a strong correlation between site 
and malignant transformation. Schepman et al. (14) studied 101 patients with lesions on the 
tongue or floor of mouth and 15 (14.9%) developed oral cancer, compared to 5 of 65 (7.7%) 
whose lesions were located elsewhere, but this was not statistically significant. In a second 
study by Dost et al. (15) the malignant potential of 383 dysplastic lesions in 368 patients was 
determined. Although the tongue (48.8% of lesions) and floor of mouth (11.5%), together 
were the most common sites, and the tongue had the highest transformation rate of 1.4% 
per year, the relationship between site and transformation was not significant.  Holmstrup et 
al. (16) followed 236 patients with 269 lesions, and found a malignant transformation rate of 
12% for lesions treated surgically and 4% for lesions observed. The only significant 
prognostic factors were size and type of lesion (homogenous versus non-homogenous). The 
site of the lesions was not significant.  
In summary, most studies and clinical papers do emphasise the lateral and ventral tongue 
and floor of the mouth as areas of particular clinical concern, and this may be due to their 
over exposure to carcinogens due to pooling of saliva in alcohol and tobacco users (17). In 
their systematic review, Warnakulasuriya and Ariyawardana (6) found that, on a global basis, 
the buccal mucosa was the most common site overall (18.4% of lesions), but had the lowest 
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rate of malignant transformation (3.35%), whereas the tongue accounted for 16.14% of 
lesions, but was the most common site for transformation with a rate of 24.22%. The next 
PRVW FRPPRQ VLWH ZDV WKH FRPELQHG ³WRQJXH DQG IORRU RI PRXWK´ DW D UDWH RI 
However, these data may hide some geographic variations since they may apply to 
populations with the most common habits of smoked tobacco and alcohol. In other 
populations other sites may be more important and be associated with specific tobacco 
habits. For example, in Andhra Pradesh 71% of leukoplakias were located on the palate 
associated with reverse smoking, and in Kerala, 65% were on the buccal mucosa, 
associated with chewed tobacco (18). 
 
Clinical appearance 
Oral leukoplakia shows a variety of clinical appearances, and this had led to several 
definitions that were complicated and confusing  Leukoplakias are uniformly white or plaque-
like, with a flat or wrinkled surface that may contain fine cracks or fissures (homogenous 
leukoplakia) (Figure 1), while others are non-homogenous (Figure 2) and may have a warty, 
nodular or verrucous surface pattern ³YHUUXFRXV OHXNRSODNLD´RU may contain red areas or 
be speckled (³VSHFNOHG OHXNRSODNLD´ RU ³erythroleukoplakia´  There is consensus in the 
literature that non-homogenous lesions have a greater risk of malignant transformation than 
homogenous lesions (2-6), but it can be very difficult to compare studies because of the 
different locations and different ways of reporting malignant transformation. For example 
most large Indian studies are population or community based, often involving house-to-
house surveys (18), whereas most studies in the developed world are based on hospital 
populations or retrospective analyses of pathology records. However, a systematic review 
(19) found a global prevalence of leukoplakia of 2.6% and a malignant transformation rate of 
1.36% per year.  Warnakulasuriya and Ariyawardana (6) carried out a systematic review of 
24 studies and found an overall malignant transformation rate of between 1.5% and 34.0%, 
but there was a wide variation in the location or type of study. They found 8 studies which 
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compared homogenous and non-homogenous lesions, and all showed that non-
homogenous lesions had the highest rate of progression. In their summary analysis they 
calculated an overall transformation rate of 3.0% for homogenous lesions and 14.5% for 
non-homogenous lesions (p=0.001).  One of the largest series was published by Bánóczy 
(11) who summarised a series of papers (20-23) on a cohort of 670 Hungarian patients. 
Over a 30 year follow up period, 6% (40 cases) of leukoplakias progressed to cancer. They 
divided the lesions into three clinical variants: simplex (homogenous), and verrucous or 
erosive (speckled) (both non-homogenous).  None of the homogenous lesions (simplex) 
progressed to cancer, whereas the transformation rate for verrucous lesions was 4.6% and 
for erosive was 28.0%. The overall rate for the non-homogenous group was 13.4%. 
Expressing this data in a different way, there were 82 erosive lesions which accounted for 
74% of the oral cancers. The remaining 26% arose from 173 verrucous lesions.  Although 
the actual data may vary, Bánóczy¶Vfinding that verrucous and, especially, speckled lesions 
have the highest rates of progression have been confirmed a number of times. In the largest 
Indian study to date (18) the overall malignant transformation rates were very low (0.3% ± 
2.19%) but homogenous lesions were much less likely to become malignant.  In California, 
Silverman (24) showed that non-homogenous lesions (erythroleukoplakia) transformed in 
23.4% of cases compared to 6.5% of homogenous lesions. In a series of Norwegian patients 
(25), 14 of 157 patients with leukoplakia developed cancer, but only one of these arose in a 
homogenous lesion (1.6%) while the remainder arose from non-homogenous lesions (13 
from 97; 13.4%). Of these, 28 were described as nodular and 8 became malignant (28.6%).  
In Holmstrup et al¶V study (16), non-homogenous lesions showed a seven times increased 
risk of progression to cancer when compared to homogenous lesions (OR= 7.0; 95% CI, 
1.7,28.5).  Of all the factors which they analysed, the type of lesion was the most significant 
in predicting prognosis. A characteristic type of non-homogenous leukoplakia ± proliferative 
verrucous leukoplakia - has been described and is discussed below. 
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The use of the terms homogenous and non-homogenous leukoplakia has been severely 
criticised since it may over-emphasise the importance of white lesions and divert FOLQLFLDQV¶ 
attention away from the more significant and dangerous red lesions (26). As noted above, 
the highest rates of malignant change were noted in lesions which were described as 
speckled or erosive (11) or as erythroleukoplakia (24) ± in other words, emphasising that 
these lesions are not in fact true ³OHXNRSODNLDV´ZKLWHSODTXHVEXWKDYHDUHGFRPSRQHQW
The seminal work of Mashberg is well known and although he did not primarily study 
OPMDs, his work shows that most early oral cancers are red or have a significant red 
component (erythroplasia) (27,28). In his first major study on this subject (27) Mashberg 
identified 158 asymptomatic, early lesions in 125 patients. One hundred and twelve lesions 
were invasive squamous cell carcinomas and 46 were carcinoma-in-situ.  His major finding, 
which formed the basis of his later work and opinions (26,28) was that over 90% of the 
lesions had a red component and only 14 (9%) were described as white (of which 9 
presented on the lips). Sixty lesions (38%) were entirely red and a further 98 (62%) were red 
and white (speckled, stippled or patchy). In later studies (reviewed in 28) he confirmed these 
findings in a cohort of 236 asymptomatic cancers, of which only 6% were white. The 
remainder were entirely red (32%), had a predominant red component (32%) or were mixed 
(29%).  In his reviews (26,28) he emphasises the importance of redness as an early sign of 
cancer and expresses dismay at the over-HPSKDVLV RI ³OHXNRSODNLD´ DV D SUHPDOLJQDQW
condition, which, he claims, is a major cause of the lack of progress in early diagnosis of 
cancer.  
Erythroplakia is a well defined clinical lesion (3,7) but Mashberg is correct in that it is often 
not included in studies of OPMD (eg. 4,6,10,11,17) ± probably because it is relatively 
uncommon and therefore more difficult to study.  In their survey of 50,915 Indians, Mehta et 
al. (29) found 881 leukoplakias (1.73%) but there were only 9 cases of erythroplakia (0.02%) 
(7). In the USA, only 58 cases were identified among 64,345 biopsy samples (0.09%) (30). 
Reichart and Phillipsen (7) reviewed a number of population studies which showed a 
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prevalence of between 0.02% and 0.83%.  As suggested by Mashberg (26,28), the majority 
of erthroplakias, show invasive carcinoma or carcinoma-in-situ, so the issue of progression 
to malignancy is a moot point, since the lesion should probably be managed as malignant at 
ILUVW SUHVHQWDWLRQ ,Q 6KDIHU DQG:DOGURQ¶V VHULHV RI 58 cases (30) 51% showed invasive 
cancer and 40% showed severe epithelial dysplasia or carcinoma-in-situ at first biopsy.  The 
remaining 9% showed mild or moderate dysplasia.  For erythroplakias that do not show 
invasive cancer at first biopsy, the majority will show high risk histological features. The best 
estimates for malignant progression of these lesions can be derived from data for the 
malignant transformation of lesions showing severe epithelial dysplasia (including 
carcinoma-in-situ). A number of relevant studies are summarised in Table 2. 
 
Size 
In Holmstrup HW DO¶V. study (16) size was the only other factor which showed a statistical 
correlation with malignant transformation.  Specifically, lesions greater then 200mm2 were 
more likely to progress than lesions less than this size (OR=5.4; 95% CI, 1.1,26.1).  In a 
study of 50 patients from Northern Ireland, Napier et al. (37), found that the risk of 
transformation was 6 times greater in patients with large confluent lesions that extended 
over more than one anatomical site compared to smaller localised lesions. Of 12 patients 
with such lesions, 7 developed oral cancer.  They also found 11 patients with lesions at one 
anatomical site, five of whom developed cancer, a risk 4 times greater than in those with 
multiple lesions. It was notable that of the 27 patients with multiple non-confluent lesions, 
only 5 progressed to malignancy. Warnakulasuriya and Ariyawardana (6) recommended on 
the evidence from their systematic review that any leukoplakia that exceeds 200mm2 has a 
higher risk for malignant transformation.  
 
Age/duration 
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Most studies agree that although OPMDs are chronic and persistent, the risk of malignant 
change is higher within the first five years after diagnosis.  In their systematic review, 
Warnakulasuriya and Ariyawardana (6) found 5 studies that had analysed transformation by 
age groups. Overall, although lesions tended to progress early in their natural history, 
transformation rates were higher in older individuals.  In a large Swedish study, involving 782 
patients with leukoplakia, the highest transformation rate (6.4% in five years) was found in 
those aged 70-89 years, compared to less than 1% in all age groups below 50 years (38).  In 
Bánóczy¶V Hungarian series (11) the peak incidence of leukoplakia was in the sixth decade, 
but the highest rates of transformation were in the seventh decade (7.1%) or in patients over 
71 (8.2%).  They also noted however a transformation rate of 7.4% in the fourth decade.  In 
his series of 157 Norwegian patients with leukoplakia, Lind (25) found that lesions tended to 
progress soon after first diagnosis. Of the 14 cases which progressed, 5 patients developed 
oral cancer in the first year and six within the next eight years.  In the Netherlands, it was 
noted that the number of transformed lesions increased with longer follow-up times (14). 
They estimated that 50% of patients with leukoplakia would develop a tumour within 200 
months of diagnosis, but the median time to malignant transformation was only 32 months. 
They found that overall, 12.4% of lesions transformed and that the mean age of first 
presentation of the patients who developed cancer was 67.1 years, compared to 55.8 years 
for patients who did not develop cancer.  
The large studies from India and the developing world support the view that lesions are likely 
to develop and progress in older individuals since the highest incidences of leukoplakia are 
consistently in younger age groups than oral cancer (18,29,39,40). For example, the highest 
incidence of leukoplakia in Kerala was found in 35-54 year olds while the highest incidence 
of oral cancer was in the 55-74 year age group (40). 
 
Gender 
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Warnakulasuriya and Ariyawardana¶V UHYLHZ (6) identified 12 studies that had looked at 
gender and malignant transformation.  In nine of the twelve studies, the rate of 
transformation was greater in females than males, with an overall rate of 13.1% for females 
and 1.7% for males (p<0.001).  The highest rate in females was 40.6%, reported from 
Northern Ireland (37) and the lowest was found in Denmark (3.7%) (41). In males the highest 
rate was 28.6% in the United Kingdom (13) and the lowest was 0% in the Netherlands (42). 
Another study in the Netherlands however, found 76 males with leukoplakia of whom 4 
developed oral cancer (5.3%), but of 90 females with lesions 16 females progressed (17.7%) 
(14).  In a Norwegian study, Lind (25) found lesions in 102 males and 55 females, but oral 
cancer developed in 8 males (7.8%) and six females (10.9%). Nonetheless, it is still unclear 
why women are more predisposed to malignant transformation than men. Global genomic 
arrays may illustrate a differential gene expression that explains this gender predilection.      
The propensity for females to have a higher risk of malignant transformation is despite the 
fact that lesions are less common in females. In Sweden, Axell (43) found a male:female 
ratio of 6:1, but this reduced to 5:2 among non-smokers. In the USA the male:female ratio 
was reported as 2:1 (44). In the large Indian studies (18,29,39,40,45) females were much 
less likely to have lesions, but this was related to the fact that they were less likely to use 
tobacco.  
 
Habits 
Tobacco use and consumption of alcohol are well established aetiological factors for the 
development of OPMD, but there is also good evidence that risk of progression is related to 
the use of, or continued use of, these habits. Lesions in non-smokers (sometimes referred to 
DV ³LGLRSDWKLF OHXkoplakLD´ VHHP WR EH DW D KLJKHU ULVN RI SURJUHVVLRQ WR FDQFHU (17). In 
Schepman¶s study in the Netherlands (14) the three factors associated with the greatest risk 
of transformation, were non-homogenous lesions (p=0.01), being female (p<0.025) and 
female non-smokers (p<0.05). There were no statistically significant associations with 
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smoking in males, nor for alcohol in either gender. In another study in the Netherlands (42) 3 
of 46 patients developed oral cancer and all were non-smokers.  In California, Silverman et 
al. (24) found that lesions in smokers and non-smokers showed quite different patterns of 
behaviour. Forty five patients in their cohort of 257 developed an oral cancer during an 
average follow-up time of 7.2 years. There were 133 lesions in patients who were smokers 
and continued to smoke and of these, 21 (16%) transformed to oral cancer and 49 lesions 
(37%) either regressed or disappeared. Of 74 non-smokers, 24% (18 patients) developed 
oral cancer, but in only 2 patients (3%) did lesions regress or resolve. The remaining 50 
patients stopped smoking after diagnosis and among these, 6 (12%) developed oral cancer, 
and in a further 22 (44%) lesions became smaller or resolved. In a Swedish study (38), the 
cumulative frequency of oral cancer development was 3.1% over 5 years in non-tobacco 
users compared to only 0.4% in smokers.  In her large Hungarian studies, Bánóczy (11) 
found that the proportion of patients who smoked was higher in those with leukoplakia that 
did not progress (87%) than in those who developed carcinoma (78%) and concluded that 
there was a greater tendency for malignant transformation in leukoplakias not associated 
with tobacco.  In a study in England, Ho et al. (46) found that the most significant predictor of 
malignant change was non-smoking status. They studied 91 patients with histologically 
diagnosed dysplasia, of whom 20 were never-smokers, 29 moderate smokers and 42 were 
heavy smokers. After 5 years of follow up, 13 never smokers (43%) developed cancer 
compared to 11% and 4% respectively in the other two groups (p=0.001).  
These data suggest that although tobacco is an important aetiological factor for the 
formation of keratotic lesions, other factors must be important for these lesions to progress 
to malignancy. The increased risk in non-smokers suggests that an underlying genetic 
predisposition may also be involved in at least a proportion of cases.  It should be noted 
however, that not all studies have been able to demonstrate a relationship between tobacco 
use and progression. Warnakulasuriya and Ariyawardana (6) did not identify any papers 
which analysed smoking as a factor, and neither Dost et al. (9) nor Holmstrup et al. (16) 
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found any significant associations between smoking and progression to malignancy. With 
regards to alcohol, there is much evidence to implicate it as an aetiological factor, but no 
evidence for a role as a risk factor for progression in established lesions (4,6,9,17,47). The 
use of betel quid and areca nut are also risk factors, and are considered below under oral 
submucous fibrosis. 
 
Histological prognostic factors for progression to cancer 
Epithelial dysplasia 
Although it is established that OPMD are statistically more likely to become malignant, it is 
not inevitable that each lesion will progress to cancer. Although the clinical parameters 
described above may help in clinical risk assessment, the gold standard diagnostic 
procedure is to undertake a biopsy for histological examination. This will enable the 
pathologist to exclude any specific diagnosis, and to evaluate any tissue changes, the most 
significant of which are features of cytological atypia and distorted epithelial architecture, 
which together are referred to as oral epithelial dysplasia (OED) (2,3). It is not inevitable 
however, that a dysplastic lesion will transform into cancer, and non-dysplastic lesions may 
also progress.  Silverman et al. (24) showed that 36% of dysplastic lesions progressed to 
carcinoma, but also that 16% of leukoplakic lesions without evidence of dysplasia 
progressed.  Clinical or histological biomarkers are desperately needed to improve our ability 
to distinguish lesions that may progress from those that will not (2,48), but, given the 
complexity of the oral carcinogenesis process and the lack of any proven predictive 
biomarkers in large prospective cohorts, surgical biopsy and histopathological grading of 
OED is regarded as the gold standard in managing these patients (2-5,49,50).  
Historically, several terms including dyskeratosis, epithelial atypia, squamous intraepithelial 
neoplasia (SIN) or squamous intraepithelial lesions (SILs) have been used to describe 
epithelial changes that precede development of oral cancer. However, for lesions of the oral 
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cavity, OED is still currently regarded as the preferred terminology (1-3,49).  The latest 2017 
WHO classification system (3) uses a combination of architectural and cytological features 
(Table 3) in an attempt to provide a more objective approach to the diagnosis and grading of 
OED.  Pathologists should use these criteria to grade lesions, but several grading systems 
have been developed and there is, as yet, no international consensus as to which should be 
used (2,3). A major problem, is that the process of grading is subjective and has low levels 
of intra- and inter-observer agreement (2,15,51-53).  Many pathologists grade lesions into 
mild, moderate, and severe dysplasia based on the extent and degree of the changes listed 
in Table 3 (2-4,49).  Mild dysplasia defines a lesion where the architectural and cytological 
changes are minimal and are limited to the lower third of the epithelium, whilst moderate 
dysplasia demonstrates changes involving up to two-thirds of the full thickness of the 
epithelium. Severe dysplasia displays more marked changes, which may extend beyond the 
lower two thirds of the epithelium. Carcinoma-in-situ is regarded as the most severe form of 
severe dysplasia, and involves changes through the entire epithelial thickness, but in the oral 
cavity, even these lesions may show a degree of surface keratinisation. In an attempt to 
improve the reliability of grading, a number of authors have developed a binary grading 
scheme (54-56), which is now recommended by the WHO (3), although it is recognised that 
further validations and clinical studies are needed.  More precisely, the 2017 WHO binary 
grading system uses metrics for evaluating cytological and architectural features (Table 3) to 
stratify oral epithelial dysplastic lesions into either low-grade or high-grade OED (3). 
However, in their studies, Kujan et al. (54,55) demonstrated that the binary system showed 
superior reliability and intra- and inter-observer agreement compared to the 5-scale WHO 
grading system from 2005 (57).  
The ultimate goal of OED diagnosis and grading is to provide patients with the best 
management and care.  Clinicians are more likely to intervene when they came across a 
patient with moderate or severe OEDZKHUHDVD³ZDLWDQGVHH´SROLF\PD\EH adopted for 
lesions showing only mild dysplasia (58).  Dost et al. (15) demonstrated that 4.1% of mild 
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dysplasias underwent malignant transformation and advocated the surgical removal of all 
OED cases, irrespective of their histopathological grade. Nevertheless, whether complete 
resection of all OED cases is warranted will not be discussed here, given that this topic is 
beyond the scope of our review and has been well reviewed by others (5,16,50,59).  
As it stands, grading of OED is still the most important prognostic factor for malignant 
transformation (2-4). However, even for severe epithelial dysplasia studies have shown that 
the malignant transformation rate varies considerably, from 3% to 50% (Table 2), and 
appears to be heavily dependent on the study design and population characteristics (17).  
Most studies agree that the risk of progression increases with the grade of OED.  A meta-
analysis by Mehanna et al. (60) pooled data from 14 non-randomised cohort studies and 
estimated that the mean rate of malignant transformation was 12.1% (CI: 8.1%, 17.9%), with 
a wide variation between the different studies (0%-36.4%), and a follow-up time ranging from 
0.5-16.0 years.  They also found a significant correlation between the OED grade and 
malignant transformation.  The estimated mean progression rate of mild/moderate dysplasia 
was 10.3% (CI: 6.1%, 16.8%) compared to 24.1% (13.3%, 39.5%) for severe dysplasia/CIS. 
Sperandio et al. (61) examined retrospectively the prognostic value of OED grading in a 
large cohort of 1,401 patients.  Overall, 3.5% (49 of 1409) of patients developed oral cancer 
during a follow-up period of 5 to 15 years.  The transformation rate of non-dysplastic lesions, 
was 0.012% (14 of 1,182) compared to 6% (6 of 105), 18% (14 of 76), and 39% (15 of 38) 
for mild, moderate, and severe dysplasia respectively.  In Warnakulasuriya HW DO¶V study 
(36), the severity of OED was the most significant prognostic indicator (p<0.0001). The 
transformation rates for mild, moderate and severe dysplasia were 4.8%, 15.7% and 26.7% 
respectively.  These studies strongly support OED grading as an important marker for risk of 
malignant progression.  
Using their binary system, Kujan et al.  JUDGHG  OHVLRQV DV ³KLJK-ULVN´ RU ORZ-ULVN´
based on a combination of the architectural and cytological features shown in Table 3 (54). 
Twenty eight of 35 cases (80%) graded as high-risk progressed to cancer, compared to 5 of 
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33 low±risk lesions (15%).  The binary grading had good prognostic value with a sensitivity 
and specificity of 0.85 and 0.80 respectively. In a similar study, Liu et al. (62) tested the 
diagnostic utility of the binary OED grading system in a cohort of 138 patients, with a mean 
follow-up period of 5.1 years. Of the low-grade lesions, 17 of 92 (18.5%) progressed to 
malignancy, compared to 20 of 46 (43.5%) high-grade lesions (p=0.004). They found that 
the degree of dysplasia was an independent risk factor for predicting malignant 
transformation, with high-grade dysplasia showing a 2.78-fold (CI 95%: 1.44-5.38) increased 
risk of cancer progression (62).  Nankivell et al. (56) further validated the reliability and 
prognostic usefulness of binary OED grading. These studies show that the binary system 
may have a better prognostic value and superior reproducibility than the currently more 
widely used three scale grading system (3). With further evaluations, it is believed that a 
binary system will become the standard grading scheme (2,3).  There is also good evidence 
that the accuracy and prognostic reliability of dysplasia grading can be improved by careful 
training and by consensus reporting by at least two pathologists (2,3,55,65,66).  
Several studies however, have not been able to find a relationship between epithelial 
dysplasia and malignant progression. Warnakulasuriya and Ariyawardana (6) found 5 papers 
which had correlated OED grade to malignant transformation, only 3 of which found a 
significant relationship (14, 46, 62).  Others have not been able to find a statistical correlation 
and have shown that non-dysplastic or low-grade lesions may also progress (15,16,24,63).  
This contradicts the view that leukoplakic lesions without dysplasia, or mildly dysplastic 
lesions are entirely harmless, and has led to calls WRGURSWKH³ZDLWDQGVHH´approach and 
for more active surgical intervention in the management of OPMDs (15,16,59). 
Despite these uncertainties, the majority of the literature supports the view that OED carries 
a significant risk for malignant transformation and that it must be considered in the process 
of managing the clinical risk of progression of OPMDs. However, clinicians should 
acknowledge that pathologists report on the tissue they receive and that the 
histopathological findings are highly dependent on correct and representative sampling of 
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the lesion. Holmstrup et al. (64) compared the biopsy diagnosis and the final diagnosis after 
surgical removal in 101 OPMDs. In 35% of cases they found that the biopsy had 
underdiagnosed the extent of disease, including 7 cases of squamous carcinoma which had 
shown only moderate, mild or no dysplasia on incisional biopsy, and may have been 
UHJDUGHGDV³ORZ-ULVN´ OHVLRQV7KHDXWKRUVFRQFOXGHd that histological grading of OED on 
biopsies is unreliable and that other factors must be considered for the prediction of 
malignant transformation of OPMDs.   
 
Biomarkers as predictors of progression. 
The Holy Grail in terms of risk assessment is to discover a biomarker that can be used in a 
histological or chairside test to predict malignant transformation of oral lesions.  There have 
been many studies investigating various potential markers, but to date no single biomarker 
has proved to be of clinical value. In a systematic review, Smith et al. (67) found more than 
2,500 publications addressing the issue of biomarkers in dysplasia, but only 13 met the 
criteria of longitudinal design, with adequate follow-up and well-defined diagnostic criteria.  
Overall they found that 113 biomarkers had been analysed. The most common of these was 
p53 (found in almost 90 papers and in six of the 13 included studies), followed by 
proliferation markers (Ki67 and PCNA; 20±40 papers).  Other markers including cell cycle 
proteins, loss of heterozygosity (LOH), and a range of cell surface and stromal proteins were 
studied in relatively few papers.  The authors recognised the limitations of a review of this 
sort, and the variability in the quality of identified papers. Nevertheless, they were able to 
suggest that LOH, survivin, MMP9 and DNA content may be associated with risk of 
progression. Overall, however they concluded that there is currently no strong evidence for 
the use of any biomarker in the prognosis of OPMDs. 
Others have come to similar conclusions, and have been unable to identify any markers 
which have yet been fully evaluated or are suitable for use in a routine diagnostic setting 
(48,59,67-69).  Many studies have examined various aberrations in the genome as potential 
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markers of progression (reviewed in 48,59,67-68). These include LOH and gene expression 
signatures but no single aberration has been found to be predictive. Analysis of DNA content 
(ploidy) provides a simple measure of gross genetic aberrations and is known to be highly 
associated with malignancy (70).  Analysis of DNA aneuploidy may be one potentially useful 
biomarker that is yet to be fully exploited. Recently, Alaizari et al. (71) undertook a meta-
analysis to determine if aneuploidy was a useful marker to predict malignant progression in 
OPMDs.  They identified five studies that had assessed the predictive value of ploidy 
analysis (61,72-75), and found that aneuploid lesions had a 3.12 (CI: 1.86, 5.24) fold 
increased risk of malignant transformation. All studies also showed that aneuploidy was 
associated with increasing severity of dysplasia. In their own study for example (61), they 
found a significant correlation between dysplasia grade and DNA ploidy (p<0.001). Forty-
nine of 110 (44.5%) cases of severe dysplasia were aneuploid compared to only 14.0% of 
mild dysplasias and 9.5% of non-dysplastic lesions. Of 32 lesions that progressed to 
malignancy 20, (62.5%) were aneuploid, compared to only 39 of 241 (16.2%) lesions which 
did not progress.  Torres Rendon et al. (72) found that 14 of 42 (33.3%) OED that 
progressed were aneuploid, compared to only 5 of 44 (11.3%) that did not progress 
(p=0.01). Of 19 OED that were aneuploid 74% showed malignant progression compared to 
only 42% of the diploid lesions. Although further work and prospective trials are needed, 
these studies suggest that aneuploid dysplastic lesions have a higher risk of malignant 
progression. Aneuploidy can now be measured using image cytometry and its application to 
cytology samples may soon result in rapid and reliable non-invasive tests for risk 
assessment of oral lesions (76).  
 
HPV associated epithelial dysplasia 
In a meta-analysis of studies up to 1997, Miller and Johnstone (76) found that Human 
Papilloma Virus (HPV) was more likely to be detected in precancerous lesions than in 
normal oral mucosa.  HPV was detected in 10% of normal tissues compared to 22.2% of 
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non-dysplastic leukoplakias, and 26.2% of dysplastic lesions.  Subsequently, the relationship 
between high-risk HPV and oropharyngeal squamous cell carcinoma has become well 
established, but the role of HPV in OPMD remains uncertain.  HPV-associated epithelial 
dysplasia is now well recognised (78) and increasing numbers of cases are being reported 
(79,80), but there are few studies with long-term follow up and the risk of progression of HPV 
positive lesions is not yet known. Recently however, a study by Lerman et al. (81) suggests 
that HPV positive OED may have a high risk of malignant progression. They undertook a 
detailed analysis of 53 cases of HPV-associated OED. All cases showed the characteristic 
histological features associated with HPV infection (78) and most (88.7%) arose in males 
and involved the tongue or floor of the mouth (77%). Eight of the 53 cases (15%) were 
associated with invasive squamous cell carcinoma. Further, p16 has been postulated as a 
good surrogate marker for high-risk HPV types as a high association of over 90% between 
the positive p16 and high-risk HPV types using DNA in situ hybridization was reported (81). 
 
Risk of progression of other, defined, oral lesions 
Proliferative verrucous leukoplakia 
Proliferative verrucous leukoplakia (PVL) is a multifocal, recurrent and exophytic variant of 
leukoplakia with a high rate of malignant progression. In a systematic review and meta-
analysis, Abadie et al. (82) examined 23 papers with follow-up data. They found a malignant 
transformation rate of 63.9%.  Most papers were single case reports, but of 8 papers that 
reported on a series of more than ten cases, the rate of progression varied from 33% (83) to 
100% (84).  PVL is diagnostically challenging and can often only be diagnosed 
retrospectively after careful clinical and pathological correlation shows a history of persistent 
or recurrent and multifocal lesions.  Early lesions are often flat plaque-like leukoplakias, but 
as the disease progresses, lesions become multifocal (proliferative) and increasingly 
exophytic or non-homogenous (verrucous). The existing evidence indicates a higher 
frequency in older females (>60 years of age) with gingiva the most commonly involved site 
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followed by buccal mucosa and tongue (82, 85-87). Gingival and palatal lesions are also the 
most likely to undergo malignant transformation (85, 88,89).  The aetiopathogenesis is 
poorly understood and there appears to be no correlation with alcohol, tobacco chewing, 
smoking or HPV infection (82, 85, 86).  The overall mortality rate is also somewhat unclear 
with some studies reporting 60% 5-year survival whereas others suggest it to be less 
aggressive.  In their review, Pentenero et al. (85) estimated an overall mortality of 30%.  
Histologically, PVL can show a range of features which may change over time. These 
include  simple hyperkeratosis, and verrucous hyperplasia with a verruciform surface pattern 
and wide bulbous rete pegs.  However, although there are prominent architectural changes, 
cytological atypia is minimal and conventional OED grading cannot be used as a predictive 
PDUNHU  $ ³SXVKLQJ´ LQYDVLYH IURQW EHOow the level of the basement membrane of the 
adjacent normal mucosa is suggestive of progression to verrucous carcinoma, but often 
lesions progress to conventional invasive OSCC.  Immunocytochemical staining for 
proliferation markers (MCM-2) and DNA ploidy analysis have been suggested to aid 
prediction of malignant transformation (90).  Because of their extent, lesions are usually 
excised conservatively, but recurrence rates remain high (>70%) even if a more radical 
approach is undertaken (82,85, 91). The average time for malignant transformation is 
estimated at 5-6 years after initial presentation. Close follow-up and repeat biopsies are 
essential to ensure early diagnosis and appropriate treatment.   
 
Oral Lichen planus 
Predicting the malignant potential of oral lichen planus (OLP) is challenging due to 
RYHUODSSLQJ IHDWXUHV ZLWK RUDO OLFKHQRLG OHVLRQV 2// DQG WKH SUHVHQFH RI D µOLFKHQRLG¶
inflammatory infiltrate which is commonly seen in dysplastic lesions.  Many studies have not 
used strict diagnostic criteria, making the data very difficult to interpret.  Although a small 
proportion of OLP lesions may progress to oral cancer, it is important to distinguish OLP 
from OLL since the latter seem to have a higher transformation rate.  Two recent systematic 
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reviews showed that OLP had a malignant transformation rate of 1.09% (92) and 0.9% (93), 
while the rates for OLL were 3.2% and 2.5% respectively. Casparis et al. (94) undertook a 
retrospective analysis of 483 biopsies of OLP (n=381) or OLL (n=102) and found malignant 
transformation rates of 1.3% and 5% respectively. 
Van der Meij et al. (95) have not been convinced that there is sufficient evidence to support 
the malignant potential of OLP. They reported that the literature showed rates of progression 
of 1.74% or less, but they were concerned regarding the veracity of the diagnostic criteria 
applied.  In their study, they applied strict clinical and histopathological criteria for diagnosis 
and identified 67 patients with OLP and 125 with OLL.  No patients with OLP progressed, but 
4 (3.2%) patients with OLL developed squamous carcinoma.  Of particular note, their criteria 
for a diagnosis of OLP included the requirement that lesions were bilateral and that they did 
not show evidence of epithelial dysplasia on histological examination.  This is a controversial 
and much debated issue (92,96), and although some may accept epithelial dysplasia as a 
feature of OLP, we do not. We would agree with Van der Meij et al. (95) and regard the 
presence of epithelial dysplasia as excluding a diagnosis of OLP. When dysplasia is present, 
lichenoid features may be prominent, but we interpret them as a lichenoid tissue reaction 
(interface mucositis) in response to the dysplastic changes, and advocate that they should 
managed in the same way as other dysplastic lesions.  This concept was first developed by 
Krutchkoff and Eisenberg in 1985 (97), who coined the term lichenoid dysplasia to describe 
oral epithelial dysplastic lesions with lichenoid features. They proposed that these lesions 
may be mistaken for OLP and that this misdiagnosis may, at least in part, explain the 
purported malignant potential of OLP.  To some extent, this concept and the term lichenoid 
dysplasia has fallen out of favour. However, the need to more carefully define OLP (95) has 
resulted in more careful considerations of the histological features, and there are good 
reason why lichenoid dysplasia should be reconsidered as a diagnostic entity (98).  
Despite these caveats, there remains some evidence that patients with OLP may be at a 
greater risk of developing oral squamous cell carcinoma (92,93,99,100).  In their large 
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systematic review, Aghbari et al. (93) found an overall malignant transformation rate of 1.1% 
in papers published since 1972. However, when they restricted their analysis to papers 
published since 2003 that used the more precise criteria for diagnosis (95), the rate reduced 
to 0.9%.  Risk factors associated with a significantly greater rate of malignant transformation 
were smoking (OR=2; 95% CI, 1.25, 3.22), alcoholics (OR=3.52; 95% CI, 1.54, 8.03) and 
HCV infection (OR=5; 95% CI, 1.56, 16.07).  In a similar review, Landini et al. (100) 
identified 65 reports of malignant transformation in lichen planus, but only 35 of these 
studies included both clinical and histological criteria for diagnosis. The overall rate of 
malignant transformation was 2.28%.  However, for studies with precise criteria the rate was 
only 1.53% compared to 2.74% in the group without histological verification.  Other studies 
agree with these findings and have also found that females may be at higher risk and that 
lesions involving tongue appear to have a higher predilection for transformation (92,94).  It is 
also noted that erosive lesions may have a greater potential for progression. This, and the 
higher risk in smokers and those who use alcohol, raises the distinct possibility that the 
association between OLP and oral cancer is coincidence, or that OLP has a predisposition to 
cancer development, only because the atrophic mucosa is more susceptible to the action of 
these carcinogens (99)  
Interestingly, an association of OLP with viral infections has also been reported. A recent 
meta-analysis (101) shows that patients with erosive OLP have a higher risk of HPV 
infection (HPV 16 and HPV18) suggesting a potential causal role in OLP progression.  
Similarly, a possible association with Hepatitis C virus has also been reported (92,93,102). 
However, it remains unclear whether the presence of infection is related to colonisation due 
to change in mucosal surface or if the virus plays an active role in OLP pathogenesis and 
progression to cancer. 
Sperandio et al. (103) identified 14 patients with well documented lichen planus, who 
developed oral cancer.  They analysed DNA content in these and found that 4 had aneuploid 
lesions. By comparison, 68 cases of OLP that had not progressed to cancer were all diploid.  
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They suggested that DNA ploidy analysis may be useful to aid prediction of malignant 
transformation in a proportion of case.  
Taken together, these data provide some evidence that patients with lichen planus may be 
at greater risk of developing oral cancer, but more precise and internationally agreed criteria 
for diagnosis need to be established.  Risk factors for malignant transformation that have 
been shown to be statistically significant include smoking and alcohol use, and infection with 
HCV.  Erosive lesions, lesions on the tongue and the presence of aneuploidy may also be 
associated with progression. 
 
Oral submucous fibrosis 
Oral submucous fibrosis (OSF) is a chronic disorder of the oral and pharyngeal mucosa 
characterised by fibrosis of the submucosa resulting in stiffness, limited opening and atrophy 
and whitening of the oral epithelium.  Although often thought to have a complex multifactorial 
aetiology it is now recognised that OSF is directly associated with use of areca nut (104-106) 
and is predominantly seen among the populations of South and South East Asia or in Asian 
populations within the UK, USA and other developed countries (104). However, only 1% -2% 
of areca nut users develop the disease suggesting that genetic predisposing factors are also 
involved (104-106).  The importance of OSF as a potentially malignant disorder was first 
recognised in 1956 (107) and since there have been numerous studies to determine the risk 
of progression.  An early long-term follow-up study in India followed 99 patients with OSF for 
17 years, and found a transformation rate of 7.6% (108). However, this was a small study 
and more recent larger studies have suggested a lower rate.  In a recent review, Ray et al. 
(109) found that the transformation rate varied from 1.9% to 7.6%. 
Some of the largest studies have been undertaken in Taiwan, where areca nut use is 
particularly prevalent.  Hsue et al. (110) identified 1458 patients with OPMDs in a 
retrospective review of histopathology records.  There were 402 patients with OSF of whom 
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8 (1.9%) developed oral cancer.  They also identified 37 patients with OSF and epithelial 
dysplasia and 2 (5.4%) of these progressed to cancer.  Of note, they found that the rate of 
progression of OSF (1.9%) was less than for epithelial dysplasia (4.65%; 6/129), 
hyperkeratosis (3.55%; 15/423;), verrucous hyperplasia (3.09%; 10/324) and lichen planus 
(2.10%; 3/143).  In a similar study in Taiwan, Wang et al. (111) reviewed 5071 patients with 
OPMDs and found an overall malignant transformation rate of 4.32%. Of 994 patients with 
OSF, 37 (3.72%) developed oral cancer.  They also identified 186 patients with OSF and 
dysplasia of whom 9 (4.84%) developed carcinomas.  It is noteworthy that these two studies 
were carried out in the same hospital and on the same population, but 10 years apart.  The 
malignant transformation rates are quite different, including that for lichen planus, which was 
only 0.52% in the second study (111) compared to 2.10% in the earlier study (110), but the 
number of cases is small.  Both these studies showed that patients with epithelial dysplasia 
and OSF had a higher transformation rate than OSF alone, suggesting that presence of 
OED in a biopsy of OSF is a predictor of high risk.  A more recent study in Taiwan has 
shown a malignant transformation rate of 9.13% for OSF ± one of the highest rates recorded 
(112).  This was a population-based study that used the records of the Taiwanese National 
Health Insurance program to identify cases of OSF and oral cancer during follow-up.  They 
identified 778 patients diagnosed with OSF over a twelve-year period, and compared the 
rate of development of oral cancer to 43568 non-OSF age and gender matched controls.  
OSF patients were more likely to be male (87.1%) and to also have lesions of oral 
leukoplakia (24.6% compared to 0.1% of controls).  In the OSF group, 71 patients (9.13%) 
developed oral cancer compared to 123 in the control cohort (0.28%).  The mean duration of 
malignant transformation was 2.5 years and 5.1 years in the OSF and controls groups 
respectively.  Among the OSF group, they identified 191 patients who had lesions of OSF 
and leukoplakia.  The malignant transformation rate in this group was 15.1% (29/191) 
compared to 7.1% (42/587) in patients with OSF alone.  In terms of risk, OSF patients were 
almost 30 times more likely to develop oral cancer than non-OSF patients (HR=29.84; 95% 
CI, 20.99,42.42) and in patients with OSF and leukoplakia the risk almost doubled 
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(HR=52.46; 95% CI, 34.88,78.91).  There is some evidence that squamous carcinoma 
developing in OSF is a clinicopathologically distinct disease, but studies from different 
geographic regions vary (103). Nevertheless, studies from the Tata Memorial in Mumbai 
(113,114) have shown that oral squamous carcinomas associated with OSF were seen more 
often in males, at a younger age and at a lower stage. Lesions were also thinner and less 
invasive and had an overall better survival.  
These studies show that OSF is an important OPMD with reported rates of malignant 
progression from 1.9% to 9.13%.  There is good evidence that the risk of progression of OSF 
is greater if histopathological analysis shows the presence of epithelial dysplasia and if 
patients have concomitant lesions of leukoplakia.  
 
Chronic hyperplastic candidiasis  
There is no consensus as to whether or not chronic hyperplastic candidiasis (CHC; candidal 
leukoplakia) should be regarded as an OPMD. The latest WHO classification (3) lists 
³&KURQLFFDQGLGLDVLV´DVDQ230'EXWJLYHVQRH[SODQDWLRQRUFULWHULDIRUGLDJQRVLVZKLOH
others do not include candidiasis as an OPMD (2,5). Anecdote and clinical experience gives 
mixed opinions.  Chronic candidal lesions may have the clinical appearance of a high-risk 
lesion, being often raised and speckled (non-homogenous), but they are most often 
encountered at sites which are rare for development of oral cancer ± the buccal commisures 
and dorsum of the tongue.  On histological examination lesions of CHC often show evidence 
of cytological atypia, but this is usually confined to an increase in (normal) mitotic figures and 
basal cell hyperplasia without pleomorphism, and may be regarded as reactive in nature. 
Lesions may also resolve after antifungal therapy, suggesting that lesions that are primarily 
caused by Candida infection are not potentially malignant.  Conversely, there is a significant 
association between fungal infection and the presence of epithelial dysplasia (115,116), but 
the debate regarding causation or association has not been resolved.  Barrett et al. (116) 
reviewed 4724 mucosal biopsies and found evidence of PAS-positive fungal hyphae in 223 
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(4.7%). There was a significant association between fungal infection and squamous 
papilloma, median rhomboid glossitis and epithelia dysplasia (p<0.01).  In particular, 
moderate and severe epithelial dysplasia were infected in 18.0% and 15.2% of cases 
respectively, with lesions on the tongue being most frequently infected.  They also showed 
that dysplastic lesions, which were infected with candida, were almost three times more 
likely to show a higher grade of dysplasia in a subsequent biopsy, suggesting a positive 
correlation between Candida and progression of dysplasia.  There is also some biological 
evidence that candida may be directly involved in carcinogenesis. This includes the finding 
that Candida isolated from leukoplakic lesions may produce carcinogenic nitrosamines (117) 
or acetaldehydes (118) and that Candida albicans can act as a promoter in a mouse model 
of 4NQO induced cancer (119).  Despite this, it has not been possible to show a true causal 
relationship between Candida and epithelial dysplasia and cancer. Two in-depth reviews 
(120,121) have concluded that the there is insufficient evidence to regard chronic 
hyperplastic candidiasis as an OPMD, but nevertheless advise that the association with 
Candida infection should be regarded as suspicious and that lesions must be kept under 
careful review and removed if they do not resolve with appropriate anti-fungal therapy.  More 
recently, Sanjaya et al. (122) have suggested that Candida has an indirect causal role in oral 
cancer and have hypothesised that in patients with tobacco smoking habits, production of 
nitrosamines by Candida albicans enhances the process of dysplasia development and 
progression to cancer.  They do not propose a role for Candida in the absence of tobacco as 
a co-factor.  
 
An approach to clinical risk assessment 
Assessing the risk of malignant change in OPMDs can be difficult, since any decision at 
each stage of the management pathway is not binary, and the clinician may be faced with a 
number of options.  The process of undertaking a clinical assessment can be considered in 
three stages ± clinical history, clinical examination, and surgical biopsy and histopathological 
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evaluation. In Figure 3 we have attempted to graphically indicate the features encountered at 
each stage that may be associated with risk. The starting point is identification of a 
suspicious lesion, which for this purpose we define as a lesion which cannot be diagnosed 
as a specific disorder on clinical examination. Specific lesions such as lichen planus or OSF 
have defined risks, and are not illustrated (see text). In Figure 3, the features encountered at 
each stage are given a risk profile, green, amber or red, indicating low, medium or high risk 
respectively. For example, the history is the first stage of clinical assessment and here, 
female non-smokers would be regarded as at a higher risk than males.  At clinical 
examination, erythroplakia has a higher risk that leukoplakia, but non-homogenous lesions 
have a higher risk than homogenous lesions, and speckled lesions are at a higher risk than 
verrucous lesions. Histopathological evaluation is a paramount and will be considered a 
FULWLFDO LQ PDNLQJ LQIRUPHG GHFLVLRQ DERXW 230'¶V PDQDJHPHQW 1RQHWKHOHVV D KROLVWLF
approach that combines the three stages of evaluation is essential to have the optimal 
outcomes of risk assessment of OPMDs.   
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Figure 1 
Homogenous leukoplakia on right lateral border of tongue; a biopsy showedmild epithelial 
dysplasia.  
 
Figure 2 
Non-homogenous leukoplakia on the lateral border of the tongue. The lesion shows irregular 
UHG DQG ZKLWH DUHDV DQG PD\ EH WHUPHG ³VSHFNOHG OHXFRSODNLD´ +LVWRORJLF H[DPLQDWLRQ
showed severe epithelial dysplasia.   
 
Figure 3. 
A simple algorithm for clinical risk assessment of OPMDs. The clinician is faced with a 
suspicious oral lesion, and at each stage of the assessment process the risk of individual 
features are illustrated as green (low risk), amber (medium risk) or red (high risk). The levels 
of risk and explanations are given in the text. 
 
